Composition for articular cavity injection comprising nucleic acid and chitosan
The present invention relates to a composition for articular cavity injection comprising a nucleic acid and chitosan. More specifically, in the present invention, it was confirmed that the sol-gel transition occurred depending on the temperature in the composition for articular cavity injection prepared through the mixing of the nucleic acid and chitosan, the proteoglycan biosynthesis of the cartilage tissue was increased by the injection of the composition and the cartilage regeneration effect was exhibited, and the pain was alleviated and the walking speed and stride which are the joint motilities were improved. Therefore, development of a therapeutic agent for arthritis having an excellent therapeutic effect using the composition for articular cavity injection comprising the nucleic acid and chitosan of the present invention is expected.
1. A composition for intra-articular injection, the composition comprising a nucleic acid and chitosan,
wherein the content of the nucleic acid is 0.1-3 wt % relative to a total weight of the composition,
wherein the content of the chitosan is 0.001-0.1 wt % relative to a total weight of the composition, and
wherein the weight ratio of the nucleic acid and the chitosan is 1:1 to 3000:1.
2. The composition of claim 1 , wherein the content of the nucleic acid is 1-2 wt % relative to a total weight of the composition.
3. The composition of claim 1 , wherein the content of the chitosan is 0.01-0.1 wt % relative to a total weight of the composition.
4. The composition of claim 1 , wherein the weight ratio of the nucleic acid and the chitosan is 10:1 to 300:1.
5. The composition of claim 1 , wherein the nucleic acid is deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or a mixture thereof.
6. The composition of claim 5 , wherein the nucleic acid is deoxyribonucleic acid (DNA).
7. The composition of claim 6 , wherein the deoxyribonucleic acid is selected from oligonucleotides, polynucleotides, and polydeoxyribonucleotides.
8. The composition of claim 1 , wherein the nucleic acid has a molecular weight of 1-100,000 kDa.
9. The composition of claim 8 , wherein the nucleic acid has a molecular weight of 10-10,000 kDa.
10. The composition of claim 9 , wherein the nucleic acid has a molecular weight of 50-3,500 kDa.
11. The composition of claim 1 , wherein the chitosan has a molecular weight of 3-1,000 kDa.
12. The composition of claim 1 , wherein the composition contains a water-soluble polymer as an additional ingredient.
13. The composition of claim 12 , wherein the water-soluble polymer is at least one selected from the group consisting of hyaluronic acid, chondroitin sulfate, glycogen, dextrin, dextran, dextran sulfate, hydroxypropyl methylcellulose, alginic acid, chitin, pullulan, collagen, gelatin, hydrolysates of all of the above, polyvinyl alcohol, polyvinylpyrrolidone, polyacrylic acid, and carboxyvinyl polymers.
14. The composition of claim 13 , wherein the water-soluble polymer is hyaluronic acid.
15. The composition of claim 1 , wherein the composition is a thermo-sensitive hydrogel.
16. The composition of claim 1 , wherein the intra-articular injection is an administration for at least one symptom selected from the group consisting of herniated nucleus pulposus, frozen shoulder, impingement syndrome, carpal tunnel syndrome, degenerative arthritis, tennis/golf elbow, complex regional pain syndrome, other tendinitis symptoms, and chronic articular rheumatism.
17. The composition of claim 2 , wherein the nucleic acid is deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or a mixture thereof.
18. The composition of claim 2 , wherein the nucleic acid has a molecular weight of 1-100,000 kDa.
19. The composition of claim 3 , wherein the chitosan has a molecular weight of 3-1,000 kDa.